Shanghai Kehua Bio-Engineering Co.,Ltd (002022.SZ)
- Previous Close
6.02 - Open
6.10 - Bid 5.97 x --
- Ask 5.98 x --
- Day's Range
5.95 - 6.13 - 52 Week Range
4.88 - 7.40 - Volume
7,404,701 - Avg. Volume
7,382,908 - Market Cap (intraday)
3.07B - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
-- - EPS (TTM)
-1.32 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date May 10, 2023
- 1y Target Est
--
Shanghai Kehua Bio-Engineering Co.,Ltd researches and develops, produces, and sells in vitro diagnostic reagents, medical testing equipment and other products in China and internationally. It offers signature products, including immunoassay & clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management, and automated comprehensive solutions for nucleic acid blood screening; automatic modular and clinical chemistry analyzer; automatic chemiluminescence immunoassay analyzers; and CLIA reagents tests. The company also provides automatic microplate reader, microplate washer, and enzyme-linked immunoassay reagents; diagnostic kit for HIV and SARS-CoV-2 IgM/IgG antibody; and fully automated nucleic acid blood screening laboratory and molecular diagnostics solutions. It serves hospitals, disease control and prevention centers, blood centers, bio-pharmaceutical enterprises, and scientific research institutions. The company also exports its products. Shanghai Kehua Bio-Engineering Co.,Ltd was founded in 1981 and is headquartered in Shanghai, the People's Republic of China.
www.skhb.comRecent News: 002022.SZ
View MorePerformance Overview: 002022.SZ
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 002022.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 002022.SZ
View MoreValuation Measures
Market Cap
3.10B
Enterprise Value
2.84B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.79
Price/Book (mrq)
0.94
Enterprise Value/Revenue
1.67
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-39.03%
Return on Assets (ttm)
-7.24%
Return on Equity (ttm)
-17.29%
Revenue (ttm)
1.7B
Net Income Avi to Common (ttm)
-665.04M
Diluted EPS (ttm)
-1.32
Balance Sheet and Cash Flow
Total Cash (mrq)
787.59M
Total Debt/Equity (mrq)
13.44%
Levered Free Cash Flow (ttm)
-77.74M